Alpha 2.0
Login Register
» Articles » PMID: 24000249

Unclassified or Unclassifiable Interstitial Lung Disease: Confusing or Helpful Disease Category?

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2013 Sep 4
PMID 24000249
Citations 4
Authors
Vincent Cottin
Athol Wells
Affiliations
Soon will be listed here.
Citing Articles

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a Analysis.

Molina-Molina M, Kreuter M, Cottin V, Corte T, Gilberg F, Kirchgaessler K Front Med (Lausanne). 2022; 9:897102.

PMID: 35783648 PMC: 9247211. DOI: 10.3389/fmed.2022.897102.

A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease.

Ryerson C, Corte T, Myers J, Walsh S, Guler S Eur Respir J. 2021; 58(6).

PMID: 34140296 PMC: 8674517. DOI: 10.1183/13993003.00276-2021.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.

Maher T, Corte T, Fischer A, Kreuter M, Lederer D, Molina-Molina M BMJ Open Respir Res. 2018; 5(1):e000289.

PMID: 30233802 PMC: 6135451. DOI: 10.1136/bmjresp-2018-000289.

A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

Ryerson C, Corte T, Lee J, Richeldi L, Walsh S, Myers J Am J Respir Crit Care Med. 2017; 196(10):1249-1254.

PMID: 28414524 PMC: 5803648. DOI: 10.1164/rccm.201702-0400PP.